miR‐200c/Bmi1 axis and epithelial–mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment
- 22 April 2015
- journal article
- research article
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 28 (4) , 431-441
Abstract
Summary: Resistance to BRAF inhibitors (BRAFi) is one of the major challenges for targeted therapies for BRAF‐mutant melanomas. However, little is known about the role of microRNAs in conferring BRAFi resistance. Herein, we demonstrate that miR‐200c expression is significantly reduced whereas miR‐200c target genes including Bmi1, Zeb2, Tubb3, ABCG5, and MDR1 are significantly increased in melanomas that acquired BRAFi resistance compared to pretreatment tumor biopsies. Similar changes were observed in BRAFi‐resistant melanoma cell lines. Overexpression of miR‐200c or knock‐down of Bmi1 in resistant melanoma cells restores their sensitivities to BRAFi, leading to deactivation of the PI3K/AKT and MAPK signaling cascades, and acquisition of epithelial–mesenchymal transition‐like phenotypes, including upregulation of E‐cadherin, downregulation of N‐cadherin, and ABCG5 and MDR1 expression. Conversely, knock‐down of miR‐200c or overexpression of Bmi1 in BRAFi‐sensitive melanoma cells activates the PI3K/AKT and MAPK pathways, upregulates N‐cadherin, ABCG5, and MDR1 expression, and downregulates E‐cadherin expression, leading to BRAFi resistance. Together, our data identify miR‐200c as a critical signaling node in BRAFi‐resistant melanomas impacting the MAPK and PI3K/AKT pathways, suggesting miR‐200c as a potential therapeutic target for overcoming acquired BRAFi resistance.Keywords
Funding Information
- National Institutes of Health (CA-116103, AR-054593S1, AR-054593)
This publication has 48 references indexed in Scilit:
- The role of microRNAs in melanomaEuropean Journal of Cell Biology, 2014
- Resistance to BRAF-targeted therapy in melanomaEuropean Journal of Cancer, 2013
- miR-200c Inhibits Melanoma Progression and Drug Resistance through Down-Regulation of Bmi-1The American Journal of Pathology, 2012
- Chromatin-modifying enzymes as modulators of reprogrammingNature, 2012
- Expression patterns of Bmi‐1 and p16 significantly correlate with overall, disease‐specific, and recurrence‐free survival in oropharyngeal squamous cell carcinomaCancer, 2011
- The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cellsJournal of Clinical Investigation, 2009
- Downregulation of miRNA-200c Links Breast Cancer Stem Cells with Normal Stem CellsCell, 2009
- Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancerJournal of Clinical Investigation, 2005
- Polycomb repression: from cellular memory to cellular proliferation and cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2002
- Mechanisms of Cancer Drug ResistanceAnnual Review of Medicine, 2002